Vitamins & Nutrition · LP-167
Ascorbic acid (Vitamin C) Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-167Vitamins & Nutrition
- Generic identity
- Ascorbic acid (Vitamin C)Tablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-167
- Generic ingredient
- Ascorbic acid (Vitamin C)
- Dosage form
- Tablet
- Proposed strength
- 100 mg; 500 mg; 1000 mg
- Proposed pack
- Blister/bottle
- Portfolio category
- Vitamins & Nutrition
About Ascorbic acid (Vitamin C)
Ascorbic acid is vitamin C, an essential nutrient involved in collagen formation and other physiological functions. Oral vitamin C can be used to prevent or correct deficiency when intake or clinical circumstances warrant it. The presence of antioxidant activity does not establish a treatment benefit for every illness. This entry does not claim that high-strength vitamin C tablets prevent infections, treat cancer or improve health in people who already have adequate intake.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Assessment considers diet, possible malabsorption, symptoms compatible with deficiency and the broader nutritional picture. Supplement use should account for vitamin C already present in other products. A medicinal tablet, dietary supplement and injectable formulation can have different regulatory and clinical contexts. The catalogue records proposed oral presentations only; their local legal category, labeling claims and patient eligibility require product-specific confirmation.
Important safety considerations
Gastrointestinal discomfort and diarrhoea can occur, particularly with excessive intake. Kidney-stone history, significant kidney disease and iron-overload disorders warrant professional advice because vitamin C can affect oxalate exposure and iron absorption. Review the contribution from multiple supplements and potential laboratory-test interference. A vitamin ingredient does not make accidental overconsumption or use in a high-risk patient automatically harmless. Serious or persistent symptoms should be evaluated rather than treated with additional supplements.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The tablet type is not specified as chewable, effervescent or conventional. Those properties and any sodium, sweetener or other excipient content require confirmation. Each listed strength must remain a distinct product specification.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review nutritional need, dietary intake, other supplements, kidney history and iron-overload risk. Confirm local regulatory classification and the exact tablet properties before making product claims.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Ascorbic acid (Vitamin C)
- Dosage form / presentation
- Tablet
- Catalogue strength
- 100 mg; 500 mg; 1000 mg
- Catalogue pack
- Blister/bottle
- Portfolio category
- Vitamins & Nutrition
Layer 02
Unresolved product-specific fields
- The catalogue lists 100 mg, 500 mg and 1000 mg tablets but does not establish whether they are conventional, chewable, dispersible or effervescent.
- Exact ascorbic-acid form, excipients, sodium/sweetener content, scoring and strength-to-pack mapping remain product-specific.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NIH ODS: Vitamin C — Health Professional Fact Sheetgovernment scientific fact sheet
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-167, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-167.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.